Stock analysts at StockNews.com assumed coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pieris Pharmaceuticals Stock Performance
Shares of NASDAQ:PIRS opened at $13.60 on Friday. The stock has a 50-day simple moving average of $15.24 and a 200-day simple moving average of $15.04. The stock has a market capitalization of $17.95 million, a P/E ratio of -1.12 and a beta of 0.61. Pieris Pharmaceuticals has a 1 year low of $6.20 and a 1 year high of $22.32.
Institutional Investors Weigh In On Pieris Pharmaceuticals
An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. purchased a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned approximately 1.21% of Pieris Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Featured Articles
- Five stocks we like better than Pieris Pharmaceuticals
- Why Are Stock Sectors Important to Successful Investing?
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- How to Start Investing in Real Estate
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
